Page last updated: 2024-09-05

enzastaurin and Diarrhea

enzastaurin has been researched along with Diarrhea in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bian, Y; Boye, M; Day, JM; Duvic, M; Hamid, O; Kim, YH; Kuzel, TM; Lin, B; Mark, LA; Musiek, A; Pinter-Brown, L; Porcu, P; Querfeld, C; Rook, AH; Rosen, ST	1
Cleverly, AL; Darstein, C; Flanagan, SD; Musib, LC; Sinha, VP; Welch, PA	1

Trials

2 trial(s) available for enzastaurin and Diarrhea

Article	Year
Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. Leukemia & lymphoma, 2011, Volume: 52, Issue:8 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Diarrhea; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Hyperkalemia; Indoles; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Recurrence; Sezary Syndrome; Skin Neoplasms; Treatment Outcome	2011
Safety, tolerability, QTc evaluation, and pharmacokinetics of single and multiple doses of enzastaurin HCl (LY317615), a protein kinase C-beta inhibitor, in healthy subjects. Journal of clinical pharmacology, 2007, Volume: 47, Issue:9 Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Half-Life; Headache; Humans; Indoles; Male; Middle Aged; Nausea; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Sleep	2007

Article

Year

Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma.

Leukemia & lymphoma, 2011, Volume: 52, Issue:8

Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Diarrhea; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Hyperkalemia; Indoles; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Recurrence; Sezary Syndrome; Skin Neoplasms; Treatment Outcome

2011

Safety, tolerability, QTc evaluation, and pharmacokinetics of single and multiple doses of enzastaurin HCl (LY317615), a protein kinase C-beta inhibitor, in healthy subjects.

Journal of clinical pharmacology, 2007, Volume: 47, Issue:9

Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Half-Life; Headache; Humans; Indoles; Male; Middle Aged; Nausea; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Sleep

2007